Literature DB >> 20520643

Clonal analysis of erythroid progenitors suggests that pegylated interferon alpha-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells.

J-J Kiladjian, A Massé, B Cassinat, H Mokrani, I Teyssandier, J-P le Couédic, N Cambier, C Almire, E Pronier, N Casadevall, W Vainchenker, C Chomienne, F Delhommeau.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20520643     DOI： 10.1038/leu.2010.120

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  27 in total

1.  Myeloproliferative neoplasms and personalized medicine: the perfect match?

Authors:  Jean-Jacques Kiladjian; Claire Harrison
Journal:  Haematologica       Date:  2015-12       Impact factor: 9.941

Review 2.  Novel and combination therapies for polycythemia vera and essential thrombocythemia: the dawn of a new era.

Authors:  Jan Philipp Bewersdorf; Amer M Zeidan
Journal:  Expert Rev Hematol       Date:  2020-11-01       Impact factor: 2.929

3.  EZH2 mutations and promoter hypermethylation in childhood acute lymphoblastic leukemia.

Authors:  Vivien Schäfer; Jana Ernst; Jenny Rinke; Nils Winkelmann; James F Beck; Andreas Hochhaus; Bernd Gruhn; Thomas Ernst
Journal:  J Cancer Res Clin Oncol       Date:  2016-05-11       Impact factor: 4.553

4.  Myelofibrosis 2012: it's complicated.

Authors:  Harper G Hubbeling; Dale M Frank; Elizabeth O Hexner
Journal:  Ther Adv Hematol       Date:  2012-06

5.  JAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment.

Authors:  Alessandro M Vannucchi; Lisa Pieri; Paola Guglielmelli
Journal:  Ther Adv Hematol       Date:  2011-02

6.  Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project.

Authors:  Giovanni Barosi; Ruben Mesa; Guido Finazzi; Claire Harrison; Jean-Jacques Kiladjian; Eva Lengfelder; Mary F McMullin; Francesco Passamonti; Alessandro M Vannucchi; Carlos Besses; Heinz Gisslinger; Jan Samuelsson; Srdan Verstovsek; Ronald Hoffman; Animesh Pardanani; Francisco Cervantes; Ayalew Tefferi; Tiziano Barbui
Journal:  Blood       Date:  2013-04-16       Impact factor: 22.113

7.  Role of TET2 mutations in myeloproliferative neoplasms.

Authors:  Elodie Pronier; François Delhommeau
Journal:  Curr Hematol Malig Rep       Date:  2012-03       Impact factor: 3.952

8.  Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera.

Authors:  Ann Mullally; Claudia Bruedigam; Luke Poveromo; Florian H Heidel; Amy Purdon; Therese Vu; Rebecca Austin; Dirk Heckl; Lawrence J Breyfogle; Catherine Paine Kuhn; Demetrios Kalaitzidis; Scott A Armstrong; David A Williams; Geoff R Hill; Benjamin L Ebert; Steven W Lane
Journal:  Blood       Date:  2013-03-13       Impact factor: 22.113

Review 9.  Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera?

Authors:  Aziz Nazha; Aaron T Gerds
Journal:  Oncologist       Date:  2016-03-14

10.  Clinical outcomes of interferon therapy for polycythemia vera and essential thrombocythemia: a systematic review and meta-analysis.

Authors:  Wenjing Gu; Renchi Yang; Zhijian Xiao; Lei Zhang
Journal:  Int J Hematol       Date:  2021-06-06       Impact factor: 2.490
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.